|
Multimedia
Images, audio, and video related to cancer research
Calendar
Meetings, seminars, and press conferences focused on cancer research
Resources
Information on cancer types, treatment, prevention, and more
 Sponsored by:
The Cancer News Portal is supported by the National Cancer Institute of the National Institutes of Health. Additional information on cancer research, prevention, and treatment is available at www.cancer.gov |
Breaking News
Key: Meeting
Showing releases 1176-1200 out of 1216. << < 43 | 44 | 45 | 46 | 47 | 48 | 49 > >>
Public Release: 8-Feb-2013
 The LancetStudy drug is first to help patients with recurrent low-grade ovarian cancer Low-grade serous ovarian cancer is less common and aggressive than the high-grade variety, yet exceptionally difficult to treat when frontline therapy fails. Contact: Scott Merville
Public Release: 8-Feb-2013
Journal of Clinical InvestigationJCI early table of contents for Feb. 8, 2013 This release contains summaries, links to PDFs, and contact information for the following newsworthy papers to be published online, Feb. 8, 2013, in the JCI: Moving toward a treatment for triple negative breast cancer; Targeting T cells in rheumatoid arthritis; New insight into RASopathy-associated lymphatic defects; and many more. Contact: Jillian Hurst
Public Release: 8-Feb-2013
Journal of Clinical InvestigationRooting out recurrent breast cancer In this issue of the Journal of Clinical Investigation, researchers led by Carlos Arteaga at Vanderbilt University identified a protein, TGF-β, that is highly expressed in triple negative breast cancer cells after chemotherapy. 
National Institutes of Health, American Cancer Society, Komen Foundation, Lee Jeans Translational Breast Cancer Research
Contact: Jillian Hurst
Public Release: 7-Feb-2013
NatureUnique peptide could treat cancers, neurological disorders, and infectious diseases UT Southwestern scientists have synthesized a peptide that shows potential for pharmaceutical development into agents for treating infections, neurodegenerative disorders, and cancer through an ability to induce a cell-recycling process called autophagy.
National Institutes of Health, National Science Foundation, Howard Hughes Medical Institute, Robert A. Welch Foundation, UK, Netherlands
Contact: Russell Rian
Public Release: 7-Feb-2013
Cell ReportsReassuring evidence: Anticancer drug does not accelerate tumor growth after treatment ends Studies in animals have raised concerns that tumors may grow faster after the anticancer drug sunitinib is discontinued. But oncologists and physicists who collaborated to analyze data from the largest study of patients with kidney cancer convincingly demonstrate that such tumor acceleration does not occur in humans. The findings, publishing online on Feb. 7th in the Cell Press journal Cell Reports, suggest that sunitinib does not cause lingering risks for patients after their treatment ends. Contact: Mary Beth OLeary
Public Release: 7-Feb-2013
Lancet OncologyLancet Oncology: Long-term side-effects of targeted therapies in pediatric cancer patients Already we know that molecularly targeted therapies may stunt the growth of pediatric patients, delay puberty or speed the onset of diabetes. And researchers are just now starting to ask about additional, sometimes unforeseen side-effects, potentially including more subtle issues such as neurocognitive, balance and motor defects. Contact: Garth Sundem
Public Release: 7-Feb-2013
PLOS GeneticsColon cancer exhibits a corresponding epigenetic pattern in mice and humans The epigenetic investigation of mice can as a result contribute to early diagnosis of cancer in humans. Contact: Markus Morkel
Public Release: 7-Feb-2013
Molecular CellProtein paves the way for correct stem cell differentiation A single embryonic stem cell can develop into more than 200 specialized cell types that make up our body. This maturation process is called differentiation and is tightly regulated. Research from BRIC, University of Copenhagen, has identified a crucial role of the molecule Fbxl10 in differentiation of embryonic stem cells and suggests the molecule as a new potential target for cancer therapy.
Danish National Research Foundation, Danish Cancer Society, Novo Nordisk Foundation
Contact: Katrine Sonne-Hansen
Public Release: 7-Feb-2013
PLOS ONETriple-negative breast cancer subtypes identified using microRNA A new, large-scale study of triple-negative breast cancer shows that small molecules called microRNA can be used to define four subtypes of this aggressive malignancy. The findings could lead to new screening methods, prognostic markers and perhaps new targeted treatments for this aggressive and often-fatal form of breast cancer.
NIH/National Cancer Institute, Stefanie Spielman Foundation for Breast Cancer Research
Contact: Darrell E. Ward
Public Release: 6-Feb-2013
NatureUniversity of Minnesota researchers discover enzyme behind breast cancer mutations Researchers at the University of Minnesota have uncovered a human enzyme responsible for causing DNA mutations found in the majority of breast cancers. The discovery of this enzyme -- called APOBEC3B -- may change the way breast cancer is diagnosed and treated. Contact: Matt DePoint
Public Release: 6-Feb-2013
NatureScientists discover how chromosomes keep their loose ends loose Scientists at the Scripps Research Institute have discovered key details of how the protein TRF2 performs a crucial chromosome-protecting function. The finding represents a significant advance in cell biology and also has implications for our understanding of cancer and the aging process.
National Institutes of Health, Novartis Advanced Discovery Institute, NIH/National Center for Research Resources, NIH/National Institute of General Medical Sciences
Contact: Mika Ono
Public Release: 6-Feb-2013
Proceedings of the National Academy of Sciences2 antibodies are better than 1 A new combination of antibodies was found to be effective in mice against triple-negative breast cancer. Contact: Yivsam Azgad
Public Release: 6-Feb-2013
British Journal of HematologyExperimental drug combination selectively destroys lymphoma cells Laboratory experiments conducted by scientists at Virginia Commonwealth University Massey Cancer Center suggest that a novel combination of the drugs ibrutinib and bortezomib could potentially be an effective new therapy for several forms of blood cancer, including diffuse large B-cell lymphoma and mantle cell lymphoma.
NIH/National Cancer Institute, National Institutes of Health
Contact: John Wallace
Public Release: 6-Feb-2013
Science Translational MedicineCompound stimulates tumor-fighting protein in cancer therapy A compound that stimulates the production of a tumor-fighting protein may improve the usefulness of the protein in cancer therapy, according to a team of researchers.
National Institutes of Health, American Cancer Society, Penn State Hershey Cancer Institute
Contact: Matthew Solovey
Public Release: 6-Feb-2013
Nano TodayTiny capsule effectively kills cancer cells Devising a method for more precise and less invasive treatment of cancer tumors, a team led by researchers from the UCLA Henry Samueli School of Engineering and Applied Science has developed a degradable nanoscale shell to carry proteins to cancer cells and stunt the growth of tumors without damaging healthy cells. Contact: Bill Kisliuk
Public Release: 5-Feb-2013
Journal of Biological ChemistryGrowth arrest in prostate cancer A previously poorly investigated signalling pathway is crucial for the growth and proliferation of prostate cancer cells. An international research team discovered this when studying the enzyme "soluble adenylyl cyclase" that produces the second messenger molecule cAMP. When the scientists inhibited the enzyme, the cancer cell proliferation was suppressed. The team led by Dr. Yury Ladilov from the Ruhr-Universitat Bochum reported together with colleagues in the "Journal of Biological Chemistry." Contact: Yury Ladilov
Public Release: 5-Feb-2013
Journal of the National Cancer InstituteMammogram every 2 years has same benefit as yearly mammogram for older women, UCSF study finds Among older women, getting a mammogram every two years was just as beneficial as getting a mammogram annually, and led to significantly fewer false positive results, according to a study led by UC San Francisco.
NIH/National Cancer Institute, American Cancer Society, Agency for Healthcare Quality and Research
Contact: Elizabeth Fernandez
Public Release: 5-Feb-2013
JAMAHospice use rises; So does aggressive care A study in the Journal of the American Medical Association documents an increase in hospice use over the last decade but also finds more ICU utilization, more repeat hospitalizations, and more late health care transitions. The data raises concern about whether aggressive care and burdensome transitions at the end of life are consistent with the wishes of patients or those of their family members.
NIH/National Institute on Aging
Contact: David Orenstein
Public Release: 5-Feb-2013
Journal of Thoracic Oncology1 out of 4 lung cancer patients in Andalusia does not receive the radiotherapy they need A recent study has revealed that 25 percent of lung cancer patients treated in Andalusian health care centers do not receive radiotherapy as established by clinical protocols. Contact: José Expósito Hernández
Public Release: 5-Feb-2013
CA: A Cancer Journal for CliniciansCancer in African Americans: Gap closing for some sites; Widening for others The cancer death rate for men declined faster among African Americans than among whites in the latest time period, narrowing the racial disparity in overall cancer death rates, according to a new report from the American Cancer Society.
American Cancer Society
Contact: David Sampson
Public Release: 5-Feb-2013
BMC MedicineObesity in dads may be associated with offspring's increased risk of disease A father's obesity is one factor that may influence his children's health and potentially raise their risk for diseases like cancer, according to new research from Duke Medicine. The study, which appears Feb. 6 in the journal BMC Medicine, is the first in humans to show that paternal obesity may alter a genetic mechanism in the next generation, suggesting that a father's lifestyle factors may be transmitted to his children.
National Institutes of Health, American Cancer Society, Fulbright,Fred and Alice Stanback Foundation
Contact: Rachel Harrison
Public Release: 5-Feb-2013
Cancer DiscoveryStudy finds potential to match tumors with known cancer drugs Researchers have found a new way to match potential cancer treatments with an individual tumor: assess the landscape of kinases and find a kinase inhibitor that goes after the highest-expressing kinases in that tumor.
NIH/National Cancer Institute, US Department of Defense, Rich Rogel Fund for Pancreatic Cancer Research
Contact: Nicole Fawcett
Public Release: 5-Feb-2013
Journal of NutritionSome omega-3 oils better than others for protection against liver disease Research has found that one particular omega-3 fatty acid has a powerful effect in preventing liver inflammation and fibrosis -- common problems that are steadily rising along with the number of Americans who are overweight.
National Institutes of Health, USDA/National Institute of Food and Agriculture
Contact: Donald Jump
Public Release: 5-Feb-2013
Proceedings of the National Academy of SciencesResearchers use new molecular inhibitors to successfully hit difficult cancer target Early laboratory tests are the first to successfully use an experimental molecular therapy to block a hard-to-target part of a protein complex linked to several types of invasive cancer. Scientists report online Feb. 4 in PNAS Early Edition the rational design of a small-molecule inhibitor they call Y16. In laboratory tests, the inhibitor helped stop the spread of cultured human breast cancer cells, especially when it was used with another compound known as Rhosin/G04.
National Institutes of Health
Contact: Nick Miller
Public Release: 5-Feb-2013
Cancer ResearchRNA promotes metastasis in lung cancer MALAT1, an RNA molecule, is a marker for progression of lung cancer. Heidelberg researchers have now found out that MALAT1 activates metastasis-promoting genes in cancer cells. In mice, blocking of MALAT1 reduced the number and size of lung cancer metastases. Contact: Sibylle Kohlstädt
Showing releases 1176-1200 out of 1216. << < 43 | 44 | 45 | 46 | 47 | 48 | 49 > >>
|
Search News Releases
|
|||||||||||||||||||||||||
Journal 
 |
||||
|
|
 |
|